Vident Advisory’s AbbVie ABBV Stock Holding History

Vident Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.5M	Buy	188,691 +12,056	+7%	+$2.59M	0.34%	59
2026 Q1	$38.4M	Buy	176,635 +25,365	+17%	+$5.63M	0.33%	58
2025 Q4	$34.6M	Buy	151,270 +2,499	+2%	+$569K	0.31%	68
2025 Q3	$34.4M	Buy	148,771 +5,909	+4%	+$1.2M	0.33%	65
2025 Q2	$26.5M	Buy	142,862 +8,859	+7%	+$1.65M	0.3%	79
2025 Q1	$28.1M	Buy	134,003 +41,386	+45%	+$8.05M	0.41%	52
2024 Q4	$16.5M	Buy	92,617 +15,110	+19%	+$2.78M	0.29%	74
2024 Q3	$15.3M	Sell	77,507 -5,242	-6%	-$978K	0.39%	52
2024 Q2	$14.2M	Sell	82,749 -215,848	-72%	-$35.8M	0.39%	53
2024 Q1	$54.4M	Buy	298,597 +54,803	+22%	+$9.44M	1.13%	6
2023 Q4	$37.8M	Sell	243,794 -1,062	-0.4%	-$155K	0.95%	9
2023 Q3	$36.5M	Buy	+244,856	New	+$35.9M	1.13%	8

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vident Advisory's ABBV Position: Q2 2026 in Review

Vident Advisory increased its AbbVie (ABBV) stake by 6.8% in Q2 2026, buying an estimated $2.59M and bringing the position to 188,691 shares worth $47.5M. The position accounts for 0.34% of the portfolio, ranked #59.

Vident Advisory first reported a position in ABBV in Q3 2023 and has held it in 12 quarters since. The position peaked at $54.4M in Q1 2024. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Vident Advisory held 188,691 shares of AbbVie worth $47.5M as of Q2 2026.
Vident Advisory bought 12,056 AbbVie shares in Q2 2026, an estimated $2.59M.
AbbVie made up 0.34% of Vident Advisory's portfolio in Q2 2026, its #59 holding.
Vident Advisory first reported a position in AbbVie in Q3 2023 and has held it in 12 quarters since.
Vident Advisory's AbbVie position peaked at $54.4M in Q1 2024.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.